Autologous Immune Enhancement Therapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  • Revathi Raj
  • M. Deenadayalan
  • G. Vimal Kumar
  • Vipin Khandelwal
  • Karuna Sri
  • Rajappa Senthilkumar
  • Samuel J. K. Abraham
  • Terunuma Hiroshi
Case Report

Abstract

Advances in current treatment regimens in childhood acute lymphoblastic leukemia (ALL) have resulted in cure rates of 75–80 %. Some molecular genetic abnormalities confer a poor prognosis. Of these, the chromosomal translocation t (9;22)—Philadelphia chromosome is associated with the worst outcome in childhood ALL. Optimal therapy for this variant of ALL includes chemotherapy as per high risk schedule, imatinib and early stem cell transplantation. We report here the successful natural killer cell-based autologous immune enhancement therapy along with chemotherapy and imatinib in a patient with Philadelphia chromosome positive ALL.

References

  1. 1.
    Aricò M, Valsecchi MG, Camitta B et al (2000) Outcome of treatment in children with Philadelphia chromosome–positive acute lymphoblastic leukemia. N Engl J Med 342:998–1006PubMedCrossRefGoogle Scholar
  2. 2.
    Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy—a practical partnership. Nat Rev Cancer 5:397–405PubMedCrossRefGoogle Scholar
  3. 3.
    Romagné F, Vivier E (2011) F1000 Med Reports 2011 3:9. doi:10.3410/M3-9
  4. 4.
    Manjunath S, Ramanan G, Dedeepiya V, Terunuma H, Deng X, Baskar S, Senthilkumar R, Thamaraikannan P, Srinivasan T, Preethy S, Abraham S (2012) Autologous immune enhancement therapy in recurrent ovarian cancer with metastases; 18 months follow-up—a case report. Case Rep Oncol. doi:10.1159/000337319 PubMedPubMedCentralGoogle Scholar
  5. 5.
    Takada M, Terunuma H, Deng X, Dewan MZ, Saji S, Kuroi K, Yamamoto N, Toi M (2010) Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer. doi:10.1007/s12282-010-0198-5 PubMedGoogle Scholar
  6. 6.
    Terunuma H, Deng X, Toki A, Yoshimura A, Nishino N, Takano Y, Nieda M, Sasanuma J, Teranishi Y, Watanabe K (2012) Effects of hyperthermia on the host immune system: from NK cell-based science to clinical application. Thermal Med 28:1–9CrossRefGoogle Scholar
  7. 7.
    Dedeepiya V, Terunuma H, Deng X, Baskar S, Manjunath S, Senthilkumar R, Murugan P, Thamaraikannan P, Srinivasan T, Preethy S, Abraham S (2011) A comparative analysis of in vitro expansion of natural killer cells of a patient with autoimmune haemolytic anaemia and ovarian cancer with patients with other solid tumours. Oncol Lett. doi:10.3892/ol.2011.498 PubMedPubMedCentralGoogle Scholar
  8. 8.
    Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356:802–807PubMedCrossRefGoogle Scholar
  9. 9.
    Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T, Matsumoto Y (2002) Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res 8:1767–1771PubMedGoogle Scholar
  10. 10.
    Kaneko T, Goto S, Kato A, Akeyama A, Tomonaga M, Fujimoto K, Miyamoto Y, Eriguchi M, Egawa K (2005) Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer. Anticancer Res 25:3709–3714PubMedGoogle Scholar
  11. 11.
    Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS (2011) A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 13:98–107PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Damodar S, Terunuma H, Sheriff AK, Farzana L et al (2006) Autologous immune enhancement therapy (AIET) a case of acute myeloid leukemia (AML)—our experience. J Stem Cells Regen Med 1(12):40–41Google Scholar
  13. 13.
    Kaneko T, Goto S, Kushima Y, Miyamoto Y, Eriguchi M, Nieda M, Egawa K (2004) A report of three patients treated with immunocell therapy with imatinib mesylate. Anticancer Res 24:3303–3309PubMedGoogle Scholar
  14. 14.
    Fregni G, Perier A, Avril MF, Caignard A (2012) NK cells sense tumors, course of disease and treatments: consequences for NK-based therapies. Oncoimmunology 1(1):38–47PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Indian Society of Haematology & Transfusion Medicine 2014

Authors and Affiliations

  • Revathi Raj
    • 1
  • M. Deenadayalan
    • 1
  • G. Vimal Kumar
    • 1
  • Vipin Khandelwal
    • 1
  • Karuna Sri
    • 1
  • Rajappa Senthilkumar
    • 2
  • Samuel J. K. Abraham
    • 3
  • Terunuma Hiroshi
    • 4
  1. 1.Pediatric Hematology, Oncology and Marrow Transplantation UnitApollo Speciality HospitalsChennaiIndia
  2. 2.Nichi-In Centre for Regenerative MedicineChennaiIndia
  3. 3.Faculty of MedicineYamanashi UniversityChuoJapan
  4. 4.Biotherapy Institute of JapanTokyoJapan

Personalised recommendations